Organisation paid for research Program year 2024 Source: CMS Open Payments

C 1 Headlands LLC

Neither a doctor nor a teaching hospital

Research payments

$11,627,315

1,025 payments

Through program year 2024, C 1 Headlands LLC is reported as receiving $11,627,315 in research payments, across 1,025 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $472,921 10
2023 Research $774,224 110
2022 Research $7,175,277 494
2021 Research $2,913,017 257
2020 Research $209,041 112
2019 Research $82,835 42

Breakdown

Who paid Research payments · program years 2019–2024
  1. Moderna TX, Inc. $10,995,824 691 payments
  2. Intercept Pharmaceuticals, Inc. $451,523 246 payments
  3. Regeneron Pharmaceuticals, Inc. $70,582 35 payments
  4. Sage Therapeutics, Inc. $50,503 35 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $26,202 2 payments
  6. GlaxoSmithKline, LLC. $24,384 13 payments
  7. Intercept Pharma Europe Ltd. $7,611 1 payment
  8. GRT US Holding, Inc. $685 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $10,980,974 685 payments
  2. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $137,547 42 payments
  3. 1011866 $127,561 85 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee $70,582 35 payments
  5. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $66,962 52 payments
  6. A Study to Evaluate the Efficacy and Safety of Sage-217 in Participants With Severe Postpartum Depression (PPD) $50,503 35 payments
  7. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $47,605 17 payments
  8. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $46,641 31 payments
  9. 1009742 $32,818 20 payments
  10. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $20,202 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record